Patents by Inventor Jack L. Strominger
Jack L. Strominger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141288Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.Type: ApplicationFiled: November 23, 2022Publication date: May 2, 2024Inventors: Torsten B. Meissner, Leonardo M.R. Ferreira, Jack L. Strominger, Chad A. Cowan
-
Publication number: 20230323288Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.Type: ApplicationFiled: November 23, 2022Publication date: October 12, 2023Inventors: Torsten B. Meissner, Leonardo M.R. Ferreira, Jack L. Strominger, Chad A. Cowan
-
Publication number: 20230303968Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.Type: ApplicationFiled: November 23, 2022Publication date: September 28, 2023Inventors: Torsten B. Meissner, Leonardo M.R. Ferreira, Jack L. Strominger, Chad A. Cowan
-
Publication number: 20230303969Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.Type: ApplicationFiled: November 23, 2022Publication date: September 28, 2023Inventors: Torsten B. Meissner, Leonardo M.R. Ferreira, Jack L. Strominger, Chad A. Cowan
-
Patent number: 11618881Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.Type: GrantFiled: January 13, 2021Date of Patent: April 4, 2023Assignee: President and Fellows of Harvard CollegeInventors: Torsten B. Meissner, Leonardo M. R. Ferreira, Jack L. Strominger, Chad A. Cowan
-
Patent number: 11492591Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.Type: GrantFiled: October 9, 2021Date of Patent: November 8, 2022Assignee: President and Fellows of Harvard CollegeInventors: Torsten B. Meissner, Leonardo M. R. Ferreira, Jack L. Strominger, Chad A. Cowan
-
Publication number: 20220112459Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.Type: ApplicationFiled: October 9, 2021Publication date: April 14, 2022Inventors: Torsten B. Meissner, Leonardo M.R. Ferreira, Jack L. Strominger, Chad A. Cowan
-
Publication number: 20210261916Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.Type: ApplicationFiled: January 13, 2021Publication date: August 26, 2021Inventors: Torsten B. Meissner, Leonardo M.R. Ferreira, Jack L. Strominger, Chad A. Cowan
-
Publication number: 20210171903Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein have modulated expression of one or more MHC-I and MHC-II human leukocyte antigens and one or more tolerogenic factors.Type: ApplicationFiled: June 22, 2020Publication date: June 10, 2021Inventors: Torsten B. Meissner, Leonardo M.R. Ferreira, Jack L. Strominger, Chad A. Cowan
-
Patent number: 10968426Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.Type: GrantFiled: May 9, 2016Date of Patent: April 6, 2021Assignee: President and Fellows of Harvard CollegeInventors: Torsten B. Meissner, Leonardo M. R. Ferreira, Jack L. Strominger, Chad A. Cowan
-
Publication number: 20190309259Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.Type: ApplicationFiled: May 9, 2016Publication date: October 10, 2019Inventors: Torsten B. Meissner, Leonardo M.R. Ferreira, Jack L. Strominger, Chad A. Cowan
-
Publication number: 20180141992Abstract: Disclosed herein are cells and populations of cells comprising a genome in which the B2M gene has been edited to eliminate surface expression of MHC Class I protein in the cells or population of cells, and methods for allogeneic administration of such cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need of such cells.Type: ApplicationFiled: November 6, 2015Publication date: May 24, 2018Applicant: President and Fellows of Harvard CollegeInventors: Chad A. Cowan, Leonardo M.R. Ferreira, Torsten B. Meissner, Jack L. Strominger
-
Patent number: 9066905Abstract: The invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolymer compositions made by solid state synthesis. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein.Type: GrantFiled: January 9, 2008Date of Patent: June 30, 2015Assignee: President and Fellows of Harvard CollegeInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Patent number: 9028835Abstract: Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. The random copolymers have amino acids alanine, lysine and one or more of the hydrophobic amino acids valine, phenylalanine, tryptophan and tyrosine. Random three-amino acid copolymer FAK efficiently suppressed EAE induced in SJL/J (H-2S) mice with the encephalitogenic epitope PLP 139-151. Random four-amino acid copolymers VYAK and tryptophan-containing VWAK were efficacious in alleviating severity and duration of symptoms of EAE induced by MBP 85-99 (SEQ ID NO:2), in a humanized mouse model expressing genes for both an HLA-DR-2 linked to multiple sclerosis (MS) in humans and for a T cell receptor from an MS patient.Type: GrantFiled: July 12, 2011Date of Patent: May 12, 2015Assignee: President and Fellows of Harvard CollegeInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Publication number: 20150030560Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.Type: ApplicationFiled: February 24, 2014Publication date: January 29, 2015Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: Rina Aharoni, Dvora Teitelbaum, Ruth Arnon, Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger
-
Publication number: 20120276049Abstract: Compositions that are fusion proteins of antibodies to dendritic cell receptors, exemplified by anti-DEC205 and anti-33D1 antibodies, to peptide sequences that are immunosuppressive or tolerogenic are provided for treatment of autoimmune diseases such as multiple sclerosis. Also provided are pharmaceutical compositions including the fusion proteins, as well as therapeutic methods for administering the fusion proteins.Type: ApplicationFiled: April 9, 2012Publication date: November 1, 2012Applicant: President and Fellows of Harvard CollegeInventors: Joel N. H. Stern, Jack L. Strominger
-
Publication number: 20110286959Abstract: Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. Fifty-mers of FEAK were effective inhibitors of MBP 85-99- or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones. These copolymers efficiently suppressed the mouse disease EAE, which was induced in a susceptible SJL/J (H-2s) strain of mice with either whole spinal cord homogenate (WSCH) or with the encephalitogenic epitope PLP 139-151 (SEQ ID NO:4). YFAK 50-mer having a molar ratio of about Y 0.8:F 0.2 inhibited binding of biotinylated MBP 85-99 epitope to HLA-DR-2 molecules more efficiently than either unlabeled MBP 85-99 or Copaxone®. YFAK and FAK copolymers efficiently suppressed EAE induced in SJL/J (H-2S) mice with the encephalitogenic epitope PLP 139-151.Type: ApplicationFiled: July 12, 2011Publication date: November 24, 2011Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Patent number: 8017125Abstract: Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. Fifty-mers of FEAK were effective inhibitors of MBP 85-99- or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones. These copolymers efficiently suppressed the mouse disease EAE, which was induced in a susceptible SJL/J (H-2s) strain of mice with either whole spinal cord homogenate (WSCH) or with the encephalitogenic epitope PLP 139-151 (SEQ ID NO:4). YFAK 50-mer having a molar ratio of about Y 0.8:F 0.2 inhibited binding of biotinylated MBP 85-99 epitope to HLA-DR-2 molecules more efficiently than either unlabeled MBP 85-99 or Copaxone®. YFAK and FAK copolymers efficiently suppressed EAE induced in SJL/J (H-2S) mice with the encephalitogenic epitope PLP 139-151.Type: GrantFiled: December 26, 2007Date of Patent: September 13, 2011Assignee: President and Fellows of Harvard CollegeInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Publication number: 20100298227Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.Type: ApplicationFiled: August 29, 2008Publication date: November 25, 2010Inventors: Rina Aharoni, Dvora Teitelbaum, Ruth Arnon, Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger
-
Patent number: 7566767Abstract: The invention provides peptide compositions, and methods of making and using therapeutic compositions for treatment of a subject for an autoimmune or an inflammatory disease. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein.Type: GrantFiled: May 15, 2003Date of Patent: July 28, 2009Assignee: President and Fellows of Harvard CollegeInventors: Jack L. Strominger, Masha Fridkis-Hareli